Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1934Neoplasms 1387Carcinoma, Non-Small-Cell Lung 1328Prostatic Neoplasms 1072Multiple Myeloma 857Leukemia, Myeloid, Acute 764Neoplasm Metastasis 693Colorectal Neoplasms 679Melanoma 671Lung Neoplasms 666Lymphoma 656Leukemia 592Lymphoma, Non-Hodgkin 588Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 522Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 473Recurrence 466Myelodysplastic Syndromes 422Lymphoma, Follicular 407Head and Neck Neoplasms 402Carcinoma, Renal Cell 377Glioblastoma 376Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 371Hodgkin Disease 352Carcinoma, Hepatocellular 325Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × Cryopyrin-Associated Periodic Syndromes × Clear all
NCT02334748 2020-05-19

A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Novartis

Phase 3 Completed
31 enrolled 7 charts

Rheumatoid Arthritis, Systemic Juvenile, Bronchiolitis Obliterans Syndrome, Arthritis, Juvenile, Arthralgia, Mevalonate Kinase Deficiency, Cryopyrin-Associated Periodic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡